Trials / Completed
CompletedNCT05166382
Impact of SomaSignal Tests on the Choice of Glucose-lowering Medications
Impact of SomaSignal Tests on the Choice of Glucose-lowering Medications: An Adaptive Implementation Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 350 (actual)
- Sponsor
- University of Colorado, Denver · Academic / Other
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to learn more about using a proteomic test called the SomaSignal Cardiovascular (CV) Risk Test in Type 2 Diabetes (CVD-T2D) to improve medical care for patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D) | Providers and patients will be informed of CVD-T2D test results that predict the risk of cardiovascular events over the next 4 years after their first research visit. |
| BEHAVIORAL | Not informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D) | Providers and patients will be informed of CVD-T2D test results that predict the risk of cardiovascular events over the next 4 years after their second research visit. |
Timeline
- Start date
- 2022-01-01
- Primary completion
- 2024-01-01
- Completion
- 2024-01-01
- First posted
- 2021-12-21
- Last updated
- 2025-03-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05166382. Inclusion in this directory is not an endorsement.